Monte Rosa Therapeutics, Inc. (GLUE) Latest Filing Signal

Latest Filing: 10-K  |  Filed Mar 17, 2026

Cross-checked across multiple AI analysts and grounded in the latest SEC filing.

powered by: earningsVibe.ai

Question:
What is the latest filing signal for Monte Rosa Therapeutics, Inc.?
Answer:
Based on earningsVibe SuperAnalyst™ synthesis of the latest 10-K, Monte Rosa Therapeutics, Inc.'s filing signal turned positive.
earningsVibe SuperAnalyst™ Verdict: TURNED POSITIVE

Signal Performance — Stock Price Since Filing

30-Day Change
Pending
from filing date
60-Day Change
Pending
from filing date

Underlying analyst views from Perplexity, Gemini, Claude, and ChatGPT

PERPLEXITY
Continuing Negative
GEMINI
Continuing Negative
CLAUDE
Turned Positive
CHATGPT
Turned Positive

Unlock the Full Filing Analysis

See full earningsSig™ and risksSig™ analysis across 5,000+ companies

Get Started Free →

No credit card required

Question:
What does Monte Rosa Therapeutics, Inc. actually do?
Answer:
Monte Rosa Therapeutics is a clinical-stage biotechnology company focused on developing novel molecular glue degraders (MGDs) that leverage the body's natural protein destruction mechanisms. The company utilizes its proprietary QuEENTM discovery engine, combining AI/ML with experimental tools, to identify and design MGDs targeting proteins previously considered undruggable. Its pipeline includes three programs in clinical development: MRT-6160 (VAV1-directed MGD for immune-mediated diseases), MRT-8102 (NEK7-directed MGD for inflammatory diseases), and MRT-2359 (GSPT1-directed MGD for metastatic castration-resistant prostate cancer). Monte Rosa has entered into significant collaborations with Novartis for its VAV1 program and other immunology targets, and with Roche for oncology and neuroscience targets.
Question:
What are Monte Rosa Therapeutics, Inc.'s revenue drivers?
Answer:
Revenue is primarily driven by upfront payments, milestone payments, and royalties from collaboration and license agreements with third parties, notably Novartis and Roche.

Cut through noisy SEC filings to find the signal faster

Source-grounded filing intelligence with one-click links back to the filing, so you can move faster and verify everything at the source.

Get Started Free →

No credit card required